REG - Immupharma PLC - Exercise of Options

ImmuPharmaAnnouncement

30/08/2022 11:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220830:nRSd6044Xa&default-theme=true

RNS Number : 6044X  Immupharma PLC  30 August 2022

 

 
30 August 2022

 

ImmuPharma plc

("ImmuPharma" or the "Company")

 

Exercise of Options

 

ImmuPharma plc (LSE : IMM), the specialist drug discovery and development
company, announces that L1 Capital Global Opportunities Master Fund
("L1") has exercised Options over 2,000,000 new ordinary shares of 1p each
("Ordinary Shares") at an exercise price of 5p per share, for a consideration
of £100,000.

 

New Ordinary Shares and Admission

The New Ordinary Shares have been allotted today and are issued credited as
fully paid and will rank pari passu in all respects with the Company's
existing issued ordinary shares.

An application will be made for the New Ordinary Shares to be admitted to
trading on the AIM market ("Admission") of the London Stock Exchange. It is
anticipated that Admission will occur on or around Monday 5 September 2022.

The New Ordinary Shares represent 0.61% of the Company's enlarged issued share
capital.

Total Shares in Issue

For the purposes of the Disclosure Guidance and Transparency Rules of the
Financial Conduct Authority ("DTR"), the Board of ImmuPharma hereby notifies
the market that following Admission, the Company's total issued share capital
will consist of 330,403,115 Ordinary Shares with a nominal value of 1p each.

This figure may be used by Shareholders as the denominator for the
calculations by which they may determine if they are required to notify their
interest in, or a change to their interest in, the Company under the DTR.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014.

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )  + 44 (0) 207 152 4080

 Tim McCarthy, Chairman
 Lisa Baderoon, Head of Investor Relations                         + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                           +44 (0) 203 368 3550 (about%3Ablank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                          +44 (0) 203 815 8880

 Patrick Claridge

 John Howes

 Bob Pountney                                                      +44 (0) 1483 413500

 SI Capital (Joint Broker)

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy
immunomodulator which is in Phase 3 for the treatment of lupus and preclinical
analysis suggest therapeutic activity for many other autoimmune diseases that
share the same autophagy mechanism of action. ImmuPharma and Alora
Pharmaceuticals signed on 28 November 2019, an exclusive licence and
development agreement and trademark agreement for Lupuzor™ to fund a new
international Phase 3 trial for Lupuzor™ and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.com.
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSDIFSSEESEEA